Design and Synthesis of Brefeldin A-Isothiocyanate Derivatives with Selectivity and Their Potential for Cervical Cancer Therapy

Molecules. 2023 May 23;28(11):4284. doi: 10.3390/molecules28114284.

Abstract

Brefeldin A has a wide range of anticancer activity against a variety of tumor cells. Its poor pharmacokinetic properties and significant toxicity seriously hinder its further development. In this manuscript, 25 brefeldin A-isothiocyanate derivatives were designed and synthesized. Most derivatives showed good selectivity between HeLa cells and L-02 cells. In particular, 6 exhibited potent antiproliferative activity against HeLa cells (IC50 = 1.84 μM) with no obvious cytotoxic activity to L-02 (IC50 > 80 μM). Further cellular mechanism tests indicated that 6 induced HeLa cell cycle arrest at G1 phase. Cell nucleus fragmentation and decreased mitochondrial membrane potential suggested 6 could induce apoptosis in HeLa cells through the mitochondrial-dependent pathway.

Keywords: apoptosis; brefeldin A; cervical cancer; isothiocyanates.

MeSH terms

  • Antineoplastic Agents*
  • Apoptosis
  • Brefeldin A / pharmacology
  • Brefeldin A / therapeutic use
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Screening Assays, Antitumor
  • Female
  • HeLa Cells
  • Humans
  • Isothiocyanates / pharmacology
  • Isothiocyanates / therapeutic use
  • Structure-Activity Relationship
  • Uterine Cervical Neoplasms* / drug therapy
  • Uterine Cervical Neoplasms* / metabolism

Substances

  • Brefeldin A
  • Antineoplastic Agents
  • Isothiocyanates